Overview

Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD)

Status:
Terminated
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to show the benefits for patients, with a high platelet count, iron deficiency and IBD, receiving intravenous iron therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Vifor Inc.
Vifor Pharma
Treatments:
Ferric Compounds